Dianthus Therapeutics, Inc.
DNTH
$19.97
$0.020.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 190.15% | 135.06% | 92.26% | 83.61% | -61.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 190.15% | 135.06% | 92.26% | 83.61% | -61.11% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 190.15% | 135.06% | 92.26% | 83.61% | -61.11% |
| SG&A Expenses | 47.43% | -25.16% | 140.65% | 143.94% | 127.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.83% | 92.24% | 88.83% | 129.42% | 13.02% |
| Operating Income | -146.34% | -89.73% | -88.55% | -132.25% | -21.16% |
| Income Before Tax | -169.24% | -70.52% | -58.05% | -93.93% | -4.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -169.24% | -70.52% | -58.05% | -93.93% | -4.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.24% | -70.52% | -58.05% | -93.93% | -4.42% |
| EBIT | -146.34% | -89.73% | -88.55% | -132.25% | -21.16% |
| EBITDA | -146.52% | -89.80% | -88.58% | -132.39% | -21.10% |
| EPS Basic | -13.87% | 80.54% | 95.96% | 93.39% | 93.84% |
| Normalized Basic EPS | -13.24% | 80.30% | 95.96% | 93.39% | 93.84% |
| EPS Diluted | -13.87% | 80.54% | 95.96% | 93.39% | 93.84% |
| Normalized Diluted EPS | -13.24% | 80.30% | 95.96% | 93.39% | 93.84% |
| Average Basic Shares Outstanding | 136.43% | 776.31% | 3,812.10% | 2,834.21% | 1,594.42% |
| Average Diluted Shares Outstanding | 136.43% | 776.31% | 3,812.10% | 2,834.21% | 1,594.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |